Napo Pharmaceuticals, Inc. 201 Mission Street, Suite 2375 San Francisco, CA 94105Jaguar Health, Inc. • September 14th, 2017 • Pharmaceutical preparations
Reference is hereby made to that certain Debt and Warrant Settlement Agreement, dated March 31, 2017 (the “Settlement Agreement”), by and among Dorsar Investment Company (together with all affiliates, collectively referred to herein as “Dorsar”), Alco Investment Company (“Alco”), Two Daughters LLC (“Two Daughters” and, together with Dorsar and Alco, collectively, the “Feinberg Parties” and each, individually, a “Feinberg Party”), and Napo Pharmaceuticals, Inc. (“Napo”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Settlement Agreement.
Jaguar Health, Inc. 201 Mission Street, Suite 2375 San Francisco, CA 94105Jaguar Health, Inc. • September 14th, 2017 • Pharmaceutical preparations
Reference is hereby made to that certain Securities Purchase Agreement, dated June 29, 2017 (the “SPA”), by and between Jaguar Health, Inc. (f/k/a Jaguar Animal Health, Inc.) (the “Company”) and Chicago Venture Partners, L.P. (“CVP”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the SPA.
Jaguar Health, Inc. 201 Mission Street, Suite 2375 San Francisco, CA 94105Note Purchase Agreement • September 14th, 2017 • Jaguar Health, Inc. • Pharmaceutical preparations
Napo Pharmaceuticals, Inc. 201 Mission Street, Suite 2375 San Francisco, CA 94105Jaguar Health, Inc. • September 14th, 2017 • Pharmaceutical preparations
Reference is hereby made to that certain Debt Settlement Agreement, dated March 31, 2017 (the “Settlement Agreement”), by and between Boies Schiller Flexner LLP (“Boies Schiller”) and Napo Pharmaceuticals, Inc. (“Napo”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Settlement Agreement.
Napo Pharmaceuticals, Inc. 201 Mission Street, Suite 2375 San Francisco, CA 94105Jaguar Health, Inc. • September 14th, 2017 • Pharmaceutical preparations
Reference is hereby made to that certain Note Purchase Agreement, dated March 1, 2017 (the “NPA”), by and among MEF I, LP (“MEF”), Riverside Merchant Partners (“Riverside”), and Napo Pharmaceuticals, Inc. (“Napo”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the NPA.
